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The circulatory system consists of large (e.g. aorta) and small (e.g. arterioles) blood vessels. Blood vessels
are not merely a system of rigid tubes but are able to increase or decrease their diameter as required. The
small blood vessels are more responsive to alterations in blood pressure. An increase or decrease in blood
pressure induces constriction or dilation of the small vessels, respectively. This is called “myogenic
response” and is necessary for regulating blood pressure and flow, particularly at the local tissue level. Much
has been elucidated with respect to cellular signaling cascades for the myogenic response, whereas less
has been known regarding a fundamental question: how are mechanical stimuli (e.g. blood pressure)
detected and, in turn, how are well-defined signaling processes initiated in the myogenic response. Growing
evidence supports the angiotensin II type 1 receptor (AT1R) serving as a novel mechanosensor and
contributing to myogenic vasoconstriction of diverse vascular beds. However, the exact downstream
signaling pathways of AT1R mechanoactivation that contribute to pressure-induced vasoconstriction are yet
to be completely delineated. We found that mechanically activated AT1R may generate a specific
downstream molecule, diacylglycerol, and in turn activate a regulatory protein, PKC, that presumably
induces actin cytoskeleton reorganization for the myogenic constriction. In addition, appropriate control of
blood flow is critical to meet the metabolic demands of tissues (e.g. pumping of cardiac muscle or brain
activity). Conversely, an impaired myogenic response can cause diverse pathophysiological results. For
example, insufficient blood flow due to excessive myogenic constriction provokes cardiac or brain ischemia,
cerebral vasospasm, or stroke. However, despite its physiological and clinical significance, mechanisms
underlying the regulation of AT1R-mediated myogenic response are incompletely understood. In regard to
this, small arteries likely exhibit negative feedback regulatory mechanisms to prevent an exaggerated
myogenic response. We tested the general hypothesis that pressure-dependent vasoconstriction is
modulated by mechanisms underlying negative regulation of AT1R signaling. Specifically, RGS (Regulators
of G-protein Signaling) proteins are viewed as important regulatory molecules for limiting myogenic
vasoconstriction. It was found in this study that ligand-dependent or independent activation of the AT1R
causes trafficking of RGS5 protein, which may precisely modulate Ang II or myogenic-mediated constriction
by terminating Gq/11 protein-dependent downstream signaling. This study will contribute to identification of
the novel mechanisms underlying myogenic responsiveness and potential therapeutic targets for
pharmacological drug discovery that can directly impact hemodynamics in the heart, brain, or other organs.
